Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Live Discussions
Live Discussions

Updated 30 November 2006

Webinar: Axonopathy in Mouse Models of AD


Thomas Bayer

Despite the availability of a wide range of animal models of Alzheimer disease, none of them are able to fully recapitulate all the facets of the disease. Axonopathy is a case in point. Although there has been renewed interest in the link between axonal swellings and pathological hallmarks of AD, such as neurofibrillary tangles and Aβ aggregates, the majority of mouse models exhibit no gross axonal abnormalities. The recently described model from Thomas Bayer’s lab at Saarland University, Germany, is one exception. Thomas Bayer presented his data on axonopathy in a bigenic mouse model of AD on 29 November 2006.

Thomas Bayer led this Webinar on 29 November 2006.

View Video Recording

Readers are invited to submit additional comments by using our Comments form at the bottom of the page.


Background Text
By Thomas Bayer

Transgenic mice have proven to be a valuable model system to study the pathological alterations in Alzheimer disease (AD). We studied APP expression, Aβ deposition, and axonal alterations in the brain and spinal cord of a bigenic transgenic mouse model expressing mutant APP751SL on a homozygous mutant (PS1M233T and PS1 L235P) PS1 knock-in background (named APP/PS1ki). These mice have been shown to develop amyloid plaques at 2 months of age with robust antecedent intraneuronal accumulation of Aβ peptides in hippocampal and cortical areas. Furthermore, they exhibit significant CA1/2 neuronal loss at 10 months of age (more than 50 percent), a pathological feature that has not been convincingly proven in most other APP transgenic mouse models (Casas et al., 2004).

Some neurodegenerative diseases including AD and amyotrophic lateral sclerosis (ALS) exhibit prominent defects in axonal transport. These defects can manifest as axonal swellings or spheroids, which correspond to axonal enlargements and aberrant accumulation of axonal cargoes, cytoskeletal proteins, and lipids. Recently, a controversial scientific debate focused on the issue of whether Aβ serves as a trigger for aberrant axonal transport in the pathophysiology of AD. We analyzed axonal neuropathology in the brain and spinal cord of the APP/PS1ki mouse model with abundant intraneuronal AβX-42 production and provide compelling evidence for axonal degeneration (see Wirths et al., 2006 and also ARF related news story). The APP/PS1ki mice showed characteristic axonal swellings, spheroids, axonal demyelination, and ovoids, which are myelin remnants of degenerated nerve fibers, in an age-dependent manner. Abundant accumulation of intraneuronal N-modified Aβ, thioflavin S-positive material, and ubiquitin was found within the somatodendritic compartment of neurons. Additionally, we have reported on age-dependent axonal degeneration in another bigenic APP751SL/PS1(M146L) transgenic mouse (Wirths et al., 2006). We conclude that the accumulation of intraneuronal Aβ-amyloid peptides might induce axonal transport deficits, which lead to axonal degradation and subsequent neuron loss in AD.



  Submit a Comment on this Live Discussion
Cast your vote and/or make a comment on this live discussion. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 


Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Live Discussion FAQs

Webinar: A Webinar is a seminar conducted remotely over the Web. Attendees view the slides through their Web browser and hear the presentations over their own telephones.

Registration: All participants are to register by clicking on the "Register for the Webinar" link.

Access: After you register, you will receive an e-mail with a link to the Webinar and a phone number.

View Webinar Instructions

Early Detection Survey Results
The Alzheimer Disease Early Detection Surveys were designed to gauge perceptions and knowledge of early detection of Alzheimer disease as a follow-up to our Early Detection Webinar. The surveys were developed in collaboration with the Geoffrey Beene Foundation.
View Researcher Survey Results [.pdf].
View Public Survey Results [.pdf].
AlzPossible Initiative
The AlzPossible Initiative is an innovative "center without walls" that enables skilled individuals to share their knowledge about best practices in Alzheimer caregiving through this open forum.
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad